Hookworms | |||||
---|---|---|---|---|---|
 | Weeks post-treatment | Albendazole – ivermectin (n = 100) | Albendazole – mebendazole (n = 101) | Albendazole – oxantel pamoate (n = 100) | Mebendazole (n = 104) |
Children positive before treatment (%) | 38 (38.0) | 43 (42.6) | 50 (50.0) | 41 (39.4) | |
No. of children cured (CR, 95 % CI) | 3 weeks | 17 (44.7, 28.6–61.7) | 21 (48.8, 33.3–64.5, p = 0.022)* | 24 (48.0, 33.7–62.6, p = 0.023)* | 10 (24.4, 12.4–40.3) |
No. of children negative (extended CR, 95 % CI) | 18 weeks | 19 (50.0, 33.4–66.6) | 23 (53.5, 37.7–68.8) | 27 (54.0, 39.3–68.2) | 14 (34.2, 20.1–50.6) |
Geometric mean: EPG | Baseline | 113.1 | 139.8 | 87.2 | 80.0 |
3Â weeks | 6.1 | 8.3 | 7.1 | 31.8 | |
18Â weeks | 6.3 | 6.3 | 6.6 | 20.7 | |
ERR (95 % CI) | 3 weeks | 94.6 (89.2–97.6)a | 94.1 (88.7–97.0)a | 91.9 (85.0–95.8)a | 60.3 (27.8–79.2) |
Extended ERR (95 % CI) | 18 weeks | 94.4 (88.8–97.5)a | 95.5 (91.5–97.8)a | 92.4 (85.4–96.3) | 74.1 (52.8–86.4) |
No. of children positive (prevalence, 95 % CI) | Baseline | 38 (38.0, 28.3–47.7) | 43 (42.6, 32.8–52.4) | 50 (50.0, 40.0–60.0) | 41 (39.4, 29.9–49.0) |
3 weeks | 26 (26.0, 17.3–34.7) | 26 (25.7, 17.1–34.4) | 31 (31.0, 21.8–40.2) | 44 (42.3, 32.7–52.0) | |
18 weeks | 27 (27.0, 18.1–35.9) | 32 (31.7, 22.5–40.9) | 34 (34.0, 24.6–43.4) | 39 (37.5, 28.0–47.0) | |
Reinfections (%, 95 % CI) | 18 weeks | 5/17 (29.4, 10.3–56.0) | 4/21 (19.0, .4–41.9) | 6/24 (25.0, 9.8–46.7) | 3/10 (30.0, 6.7–65.4) |
New infections (%, 95 % CI) | 18 weeks | 6/57 (10.5, 4.0–21.5) | 9/54 (16.7, 7.9–29.3) | 8/45 (17.8, 8.0–32.1) | 6/50 (12.0, 4.5–24.3) |